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Clinical trials for preventative therapies are complex and costly endeavors focused on individuals likely to develop disease in a short time
frame, randomizing them to treatment groups, and following them over time. In such trials, statistical power is governed by the rate of
disease events in each group and cost is determined by randomization, treatment, and follow-up. Strategies that increase the rate of
disease events by enrolling individuals with high risk of disease can significantly reduce study size, duration, and cost. Comprehensive
study of common, complex diseases has resulted in a growing list of robustly associated geneticmarkers. Here, we evaluate the utility—in
terms of trial size, duration, and cost—of enriching prevention trial samples by combining clinical information with genetic risk scores
to identify individuals at greater risk of disease.We also describe a framework for utilizing genetic risk scores in these trials and evaluating
the associated cost and time savings. With type 1 diabetes (T1D), type 2 diabetes (T2D), myocardial infarction (MI), and advanced age-
related macular degeneration (AMD) as examples, we illustrate the potential and limitations of using genetic data for prevention trial
design.We illustrate settings where incorporating genetic information could reduce trial cost or duration considerably, as well as settings
where potential savings are negligible. Results are strongly dependent on the genetic architecture of the disease, but we also show that
these benefits should increase as the list of robustly associated markers for each disease grows and as large samples of genotyped indi-
viduals become available.Introduction
Designing a randomized clinical trial for disease prevention
is a complex and costly endeavor.1 A key step is to identify
individuals likely to develop the disease during the study.
The cost of a prevention trial strongly depends on the rate
of disease onset among participants: low rates of disease
onset require large sample sizes or long trial duration to
achieve adequate statistical power. Most primary preven-
tion trials thus apply ‘‘enrichment’’strategies to recruit indi-
viduals at high risk of disease onset.2–4 Such trial design
strategies also have ethical benefits because only at-risk
subjects are exposed topotential side effects of anovel inter-
vention. Enrichment designs can also beused inother types
of clinical trials (see Simon5 for examples).
Now genetic markers have been robustly associated
with many complex diseases; it is timely to explore
how genetic information, in conjunction with clinical
information, can be used in the design of prevention
trials.6 This question can be decomposed into two more
specific questions: first, how can we accurately predict
disease risk from genetic data; and second, how can we
use predicted genetic risks to design more efficient preven-
tion trials? The question of predicting genetic risk of
complex diseases has recently been explored in various
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trial will depend on the prediction accuracy of the risk
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To evaluate the benefits and limitations of using genetic
risk-prediction models, we compare the cost and duration
of prevention trials in various scenarios, including trials
using only clinical information and trials also using
genetic information to identify high-risk subjects. To illus-
trate the issues, we consider current risk-prediction models
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(MI [MIM 608446]), and age-related macular degeneration
(AMD [MIM 603075]). Through simulation, we show that
aggregate risk scores are expected to help reduce cost of
clinical trials, sometimes modestly (T2D, MI) and some-
times substantially (T1D, AMD). Reanalyzing existing
experimental data, we further evaluate our model in the
context of T2D and AMD. Finally, we evaluate the utilitySA; 2Department of Integrative Biology, University of California, Berkeley,
line (GSK), Research Triangle Park, NC 27709, USA; 4Department of Quan-
of Cardiovascular Genetics, Institute of Cardiovascular Science, University
tute of Cardiovascular Science, University College London, London WC1E
enage SG1 2NY, UK
y of Human Genetics. All rights reserved.
erican Journal of Human Genetics 92, 547–557, April 4, 2013 547
Table 1. A Summary of Genetic and Treatment Information for Four Disease Traits
Disease Trait T2D AMD T1D MI
Current Genetic Knowledge
Population prevalence 3.0%12 11.8%a,13 0.54%14 4.0%15
Sibling recurrence risk 3.516 2.217 13.714 3.215
Heritability in liability scaleb 0.60 0.68 0.86 0.71
No. known risk variants 2918 719 4120 1221
Range of odds ratios per allele 1.06–1.37 1.31–4.31 1.05–5.49 1.13–1.28
Heritability explained by known genetic risk variants 3%–9% 46%–59% 18%–29% 1%–5%
Example Prevention Trial
Treatment effect thiazoli-dinedione22 zinc þ antioxidants23 oral insulin24 statin4
Inclusion criteriac IGT/IFG R3 baseline AMD grade NAc NAc
Average annual rate of disease onset in control arm (conventional trial) 8.7% 4.4% 2.1% 2.5%
Average annual rate of disease onset in treatment arm (conventional trial) 3.9% 3.2% 1.0% 1.5%
Trial duration 3 years 5 years 4 years 5 years
Clinical screening costd $1,500 $1,500 $1,500 $1,500
Additional per-subject cost for genetic screening $100 $100 $100 $100
Trial cost per year per subject $6,000 $3,500 $12,000 $6,000
aAMD prevalence from individuals with age 80 years or older.
bHeritability is estimated from prevalence and sibling recurrence risk.13
cInclusion criteria are applied only in the experimental data setting for T2D and AMD, not in the simulation-based studies.
dScreening and trial costs are assumed to take failure rate into account.of biobanks where a large number of already genotyped
individuals couldmake enrichment based on genetic infor-
mation particularly cost effective.Material and Methods
Framework of Genetic Enrichment Trial for Disease
Prevention
We consider a standard design framework for prevention trials as
‘‘conventional prevention trials.’’ Eligibility criteria are assessed
in potential trial participants after they provide informed consent.
Typically, this involves selecting individuals likely to develop the
disease based on clinical risk factors, such as glucose levels for
T2D3 and low-density lipoprotein (LDL) or C-reactive protein
(CRP) levels for MI.4,11 Additional risk variables such as age,
gender, or smoking history may also be incorporated into the
criteria (Table 1). Eligible participants are randomized to different
treatment arms and followed for a trial period as illustrated in Fig-
ure 1A. The treatment effect will be evaluated by comparing the
frequency of disease onset between arms. The inclusion criteria
capitalize on prognostic factors that ‘‘enrich’’ disease onset among
the trial subjects. Studying these individuals increases the number
of disease-onset events and thus reduces the sample size and the
trial cost.
In genetic enrichment trials, the inclusion criteria further
incorporate genetic information in a quantitative manner (Fig-
ure 1B). In such trials, a larger number of potential participants
are screened to obtain a small fraction of individuals at
higher risk of disease. Consequently, the targeted participants
will be at higher risk than those in conventional trials, and548 The American Journal of Human Genetics 92, 547–557, April 4, 2they will also be more likely to develop the disease during the trial
period.
Examining the trade-off between resources used in the screening
stage and the trial stage is essential to optimize the efficiency of the
trial. If the eligible criteria are too stringent, the number of poten-
tial participants to recruit and screen will be orders of magnitude
larger than that of conventional trials, and the associated costs
of screening will become a substantial portion of the total trial
cost. On the other hand, too-liberal criteria will fail to enrich the
disease onset among the trial participants, diminishing the bene-
fits of genetic screening.
Another type of possible enrichment trial builds upon a pool of
potential participants with genetic information readily available.
Several large-scale DNA biobanks are currently being established
with sample sizes up to hundreds of thousands patients25 with
consent for genetic prescreening. Individuals found to be at high
risk based on genetic risk factors determined from their banked
genetic information would be prioritized for recruitment. Given
a sufficiently large number of samples in the DNA biobank, this
strategy makes it possible to identify an extremely small fraction
of individuals at much higher risk than others without additional
screening cost (Figure 1C).
Genetic RiskModel fromKnownGenetic Risk Variants
We consider a model of individual genetic risk based on markers
known to be associated with disease traits with genome-wide
significance. Typically an individual genetic risk score is calculated
as a weighted sum of risk alleles26
gðxÞ ¼
X
i
giðxiÞ ¼
X
i
xi logðORiÞ;013
Figure 1. Frameworks of Conventional
and Genetically Enriched Prevention
Trials
(A) Conventional prevention trial not
utilizing genetic information.
(B) Standard genetic enrichment trial
following up only individuals at high
genetic risk after genetic screening.
(C) Biobank-based enrichment trial where
DNA information is available a priori and
used for inviting individuals at the begin-
ning of trial.where xi is 0, 1, or 2 copies of i
th risk alleles and ORi denotes the
odds ratio of ith risk allele estimated from previous data. When
there were multiple published risk variants in a locus, our analysis
used only variants for which pairwise r2 < 0.10. This helps ensure
independence between risk allele effects; a refined model allowing
for multiple correlated variants per locus may outperform the
approach used here. Assuming that the risk variant effects are
the same in published genetic studies and clinical trial popula-
tions, the rate of disease onset in the prevention trial participants
can be modeled as a logistic function of g(x). Thus,
Prðd j x; zÞ ¼ 1
1þ expð  m gðxÞ  dzÞ ; (1)
where d denotes disease-onset event during the trial period (e.g., 3
years for our simulated T2D trial and 5 years for our simulated
AMD trial), z is the binary indicator of randomization of treatment
assignment, and treatment effect size of d and intercept term m are
constants selected to ensure the desired rates of disease onset in
the control and treatment arms prior to genetic enrichment. We
solved m and d numerically by using Brent’s root-finding algo-
rithm. The receiver operating characteristics (ROC) of this genetic
risk score can be obtained given the risk allele frequency and
disease prevalence. All numerical estimations were based on simu-
lated genotypes of millions of individuals as described in the next
section.Simulation of Genetic Risk Scores
We evaluated the performance of genetic enrichment trial designs
by using simulated genetic and phenotype data for four diseases.
To simulate the genetic risk score by using known genetic risk vari-
ants, we simulated genotypes for amillion trial-eligible individuals
based on risk allele frequencies reported from published results.
For each simulated individual, we generated a genetic risk score
by using the published effect size of each risk variant and the simu-
lated genotypes. On the basis of the distribution of genetic risk
scores, we estimated the intercept and treatment effect parameters
to ensure that incidence in the treatment and placebo arms would
match the effects in Table 1. The likelihoods of the individualThe American Journal of Humanhaving disease were evaluated by Equa-
tion 1. To account for the uncertainty in
published odds ratios, we sampled odds
ratios from lognormal distribution defined
according to published odds ratios and
confidence intervals and then repeated
the simulation procedure with 100 dif-
ferent sets of sampled risk scores. The
‘‘very optimistic’’ and ‘‘very pessimistic’’estimates of ROC in Figure S1 (available online) use the upper
and lower bound of 95% confidence intervals of odds ratio for
each of the risk variants, respectively.
Risk Model from Known AUC Values
More generally, individual disease risk can be estimated from
genetic and clinical information independently or collectively.
In particular, we consider combined genetic and clinical risk
from cohort studies of AMD and T2D.23,27 In these studies,
an alternative measurement—the area under the ROC curve
(AUC)28—is reported. Assuming that summed risk scores are
approximately normally distributed, we estimated the variance
of genetic risk scores and effect size of treatment from AUC value,
population prevalence, and rate of disease onset in the control and
treatment arms (see the section ‘‘Details on Parameter Estimation
Based on AUC’’ for further details).
In the analysis of empirical data in AMD, the published AUC
values were adjusted for inclusion criteria of baseline grade 3 or
greater via the following equation:
AUCadj ¼ AUCorg  f2
1 f2 ;
where AUCorg and AUCadj denote original and adjusted AUC
values, respectively, and f2 is the proportion of individuals with
baseline grade 2 or less. We have assumed that no individual
with grade 2 developed the disease during the trial period, which
is a reasonable approximation given that only 8 out of 454 (2%)
individuals with baseline grade 2 developed advanced AMD
throughout the trial. For the analysis of T2D empirical data, the
AUCs were calculated with the real data. We also assumed that
the effect from clinical and genetic variables remains constant
over the trial period.
In addition to the analysis of empirical data, AUC-based
methods were also used in two hypothetical simulation settings
where 25% and 50% of the known heritability in liability scale13
could be explained by known genetic variants. This can prospec-
tively project the degree of enrichment through the use of genetic
factors that will be discovered in the future.Genetics 92, 547–557, April 4, 2013 549
Estimation of Sample Size, Trial Cost, and Trial
Duration
Given a threshold t for the genetic risk score, the expected fraction
of individuals with disease-onset events during the trial can be
modeled as
pCðtÞ ¼ E½d ¼ 1 jgðxÞRt; z ¼ 0
pTðtÞ ¼ E½d ¼ 1 jgðxÞRt; z ¼ 1;
where pC(t) and pT(t) are the rates of disease onset in the control
and treatment arms, respectively. Prior to enrichment, these
estimates correspond to the section ‘‘Example Prevention Trial’’
in Table 1. Given a false positive rate a (¼0.05) and power 1 
b (¼0.8), the required per-treatment group sample size follows29
nðtÞ ¼ 4pðtÞð1 pðtÞÞ

Z1b þ Za=2

ðpCðtÞ  pT ðtÞÞ2
pðtÞ ¼ pCðtÞ þ pTðtÞ
2
:
Given per-sample clinical screening cost Cs, follow-up cost Cf, and
proportion of eligible participants fe, the cost of a conventional
prevention trial is determined as

Cs
fe
þ Cf

n0;
where n0 represents sample size of conventional trial (see
Figure 1A).
For a genetic enrichment trial (see Figure 1B) with additional
cost Cg, for genetic screening cost Cg, if we assume that clinical
and genetic screening is performed simultaneously with clinical
screening, the overall cost becomes

Cs þ Cg
fePrðgðXÞRtÞ þ Cf

nðtÞ:
We can estimate the reduction in the required duration of a trial
with a fixed sample size and desired power by first estimating
the number of cases accrued in a trial of fixed length and then
using the simplifying assumption that the number of new cases
in each trial arm is proportional to trial length (ignoring the
competing effects of increased progression as participants age
and of decreased incidence as cases become saturated). For the
short trials examined here, the assumption is reasonable.Details on Parameter Estimation Based on AUC
Assume that the risk score g(x) ~ N(0,s2) and the treatment effect
size is d. The rate of disease onset is given by
Prðd j x; zÞ ¼ 1
1þ expð  m gðxÞ  dzÞ ;
which is identical to Equation 1. The objective is to estimate m, s2,
and d from known parameters. We use reported AUC values and
prevalence to estimate s2 and use incidence rate in the treatment
and control arms to estimate m and d.
More specifically, assuming d ¼ 0, we estimate m and s2 from re-
ported AUC values and the disease prevalence (E[djz ¼ 0]) of the
population that the AUC is calculated from. We simulated
a million random samples from the model and numerically solved
m and s2 by using Brent’s root-finding algorithm given E[djz ¼ 0]
and AUC values. Between the trial population and the population
where the AUC is calculated from, we assumed that s2 is identical.
However, because m can often be different between the two popu-550 The American Journal of Human Genetics 92, 547–557, April 4, 2lations, we re-estimated m and d among the trial subjects by using
the reported incidence rate E[djz ¼ 0] and E[djz ¼ 1], again by
using Brent’s algorithm.Results
We consider the three types of randomized two-arm
primary prevention trials illustrated in Figure 1: (1)
conventional prevention trials that screen potential partic-
ipants via eligibility criteria based on a set of clinical vari-
ables, (2) genetic enrichment prevention trials that screen
participants via clinical variables and genetic risk factors,
and (3) biobank enrichment prevention trials that identify
potential participants with high genetic risk scores prior to
clinical screening. We first evaluate the benefits of using
genetic information via simulations, and we later use
empirical data from previous studies, such as the Age-
Related Eye Disease (AREDS)23 and Whitehall II27 studies,
to account for potential overlap between clinical and
genetic risk factors.Effects of Known Risk Variants on Disease Liability
We first evaluated the potential ability of GWAS variants
to identify at-risk individuals by using simulations. We
considered risk variants identified by large-scale meta-anal-
yses for T1D,20 T2D,18 MI,21 and AMD19 as robust genetic
associations (see Table 1). Using published risk allele
frequencies and effect sizes, we simulated individual
genetic risk scores by assuming the log-additive odds
model in Equation 1. Figure 2 illustrates the distribution
of the genetic risk score for individuals with and without
disease for each trait. The distributions of the genetic risk
scores in individuals with and without disease are very
similar for T2D and MI but quite different for AMD and
T1D, where a number of loci with large effect sizes have
been described. These genetic risk profiles depend on
current knowledge of the genetic architecture of each
disease and can also be summarized as receiver operating
characteristics (ROC) curves that describe our ability to
distinguish individuals with and without disease by using
genotypes. In addition to predictions based on published
effect size estimates, ROCs summarized in Figure S1 also
include predictions that account for uncertainty in pub-
lished effect sizes.
We next used simulations to predict the relative preva-
lence of disease in individuals with high and low genetic
risk scores (Table 2). For AMD and T1D, we estimate that
selecting individuals with genetic risks in the top decile
would result in a ~3- to 5-fold increase in disease preva-
lence. Selecting individuals with genetic risks in the top
percentile would result in a ~5- to 12-fold increase in prev-
alence. For T2D and MI, ~1.5- to 2-fold increases in disease
prevalence were expected among individuals within the
top decile, whereas ~2- to 3-fold increases in risk were ex-
pected among individuals with risks in the top percentile
of genetic risk.013
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Figure 2. Distribution of Genetic Risk
Scores from Currently Known Risk Vari-
ants for Four Disease Traits
The x axis represent the genetic risk score
with respect to the individuals with the
lowest risk genotypes. The y axis represents
the fraction of individuals with disease
based on their risk score. The 95% confi-
dence intervals account for variations in
the odds ratio estimates.Utility of Known Risk Variants in Efficient Design of
Prevention Trials
Next, we estimated the utility of genetic risk scores for trial
design. We considered prevention trials for T1D, T2D, MI,
and AMD. In each case, we modeled treatment effect, trial
cost, and duration guided by previous studies (Table 1).
These simulations made two important simplifying
assumptions. First, because the largest genetic association
studies for these traits used case-control analysis to esti-
mate the impact of individual risk alleles on prevalence
(rather than incidence within a period of time), we
assumed that the impact of genetic variants on hazard-
ratios (as estimated in a case-control study) and on disease
incidence rates during trial follow-up are the same. Second,
because there is little data on how genetic and clinical
predictors interact to predict disease risk, our models
assume that genetic effects are the same in the subjects
who meet the trial’s eligibility criteria. To the extent that
clinical variables mediate the impact of genetic variants
on disease risk, this assumption will lead to optimistic
predictions of performance for trials that use both genetic
and clinical covariates for enrichment. Further, it could
mean that although we can evaluate the potential value
of genetic enrichment trials, we are not well positioned
to explore whether these trials will be more cost effective
than trials focused on individuals whose clinical profiles
indicate very high risk for disease. Our analysis of prospec-The American Journal of Humative data generated by the AREDS (on
AMD)23 and Whitehall II (on T2D)27
studies overcomes these limitations.
In our simulations, as individuals
with higher risk were targeted, the
incidence of disease gradually
increased in both treatment arms,
whereas the treatment effect size
only slightly increased (Figure S2).
This increase in the disease incidence
translates into reduced sample size
requirements (Figure 3). At the
same time, large increases in on-trial
disease incidence require progres-
sively larger samples to be screened
for clinical and genetic risk factors,
increasing screening costs. The
optimal trial cost is determined by
balancing these two trade-offs. Asshown in Table 3 and Figure 3, our simulation suggests
that cost savings up to 11% for T2D, 40% for AMD, 67%
for T1D, and 13% for MI are possible when genetic enrich-
ment is used to complement clinical risk factors. For a
fixed sample size, genetic enrichment can reduce trial
duration by ~24% for T2D and MI and by 40%–62% for
AMD and T1D.
Evaluation with Experimental Data
To complement these simulations, we applied our en-
richment trial framework to longitudinal data sets docu-
menting incidence of two specific diseases—AMD and
T2D—as well as clinical and genetic risk factors. This eval-
uation removes the simplifying assumptions required in
our simulations.
Because both clinical and genetic risk scores are
available in this empirical setting, to precisely evaluate
the additional benefits of genetic information, here we
consider (1) conventional prevention trials following
up all participants meeting eligibility criteria, (2) clini-
cally enriched prevention trials focusing on individuals
with high clinical risk scores based on clinical, demo-
graphic, and environmental variables, on top of the eligi-
bility criteria, and (3) genetically and clinically enriched
prevention trials focusing on individuals with high
combined risk scores, incorporating both genetic and
clinical risks.n Genetics 92, 547–557, April 4, 2013 551
Table 2. Disease Liability Explained by Currently Known Risk
Variants
Genetic Risk
Threshold
Fold Enrichment from Baseline Disease
Prevalence (in Parentheses)a
T2D
(3.0%)
AMD
(11.8%)
T1D
(0.54%)
MI
(4.0%)
Top 50% genetic risk 1.32 1.65 1.84 1.23
Top 20% genetic risk 1.67 2.63 3.42 1.43
Top 10% genetic risk 1.92 3.36 4.96 1.57
Top 5% genetic risk 2.17 4.07 6.82 1.69
Top 2% genetic risk 2.50 4.63 9.78 1.83
Top 1% genetic risk 2.74 4.81 12.42 1.94
aThe ratio of prevalence in the individuals with top genetic risk to the baseline
prevalence in Table 1.Age-Related Macular Degeneration
A published cohort study of 1,446 individuals at high risk
of advanced AMD allowed us to investigate our framework
for this setting.23 Participants were assayed for known
genetic risk variants in addition to clinical risk vari-
ables—age, gender, education, smoking history, and base-
line AMD grade. In total, 19% (279) of the subjects
developed advanced AMD (including unilateral and bilat-
eral and dry and wet types of advanced AMD) within 6.3
years of entering the study. The advantage of combining
clinical and genetic risk compared to clinical risk only is re-
flected in area under the ROC curve (AUC)30 statistics. A
predictive model based on clinical risk variables alone re-
sulted in AUC statistic of 0.757, whereas a predictivemodel
using combined genetic and clinical variables resulted in
an AUC statistic of 0.821. Among all risk variables consid-
ered, the baseline AMD grade was the strongest predictor of
advanced AMD. Among the 454 individuals with a low
baseline AMD grade of 2, only 8 (2%) of them developed
advanced AMD during the trial period; in contrast, among
992 individuals with a high baseline AMD grade of R3
(defined as AREDS category), 271 (27%) developed
advanced AMD during the trial period. To mimic a realistic
scenario for an AMD prevention trial from the cohort
study, we considered a prevention trial with baseline grade
R3 as inclusion criteria. We estimate that in this subset
of individuals, the AUC would be 0.637 if we used only
clinical predictors and 0.743 with genetic and clinical
predictors.
Based on these adjusted AUCs and the reported rate of
disease onset for each of the treatment groups,17 we esti-
mated the sample size requirements, trial cost, and dura-
tion for evaluating the efficacy of zinc þ antioxidant
treatment (Table 4). Our results show that, compared to
a conventional prevention trial relying only on baseline
AMD grade R3 as the inclusion criterion, enrichment
based on clinical risk scores from the demographic and
environmental risk variables could either reduce trial cost
by up to 15% by reducing sample size requirements by552 The American Journal of Human Genetics 92, 547–557, April 4, 224% or reduce the trial duration by 24% at a fixed sample
size. Enrichment with both clinical and genetic factors
can reduce trial cost by up to 33%, either by reducing
sample size requirements by 44% or by reducing trial
duration by 36%—either option corresponds to substantial
efficiency gains beyond enrichment with only clinical
characteristics.
Whereas simulation using GWAS-based effect size esti-
mates, under the assumption that there is no interaction
between clinical and genetic risk factors, suggested a poten-
tial 40% savings in prevention trial cost, this empirical
analysis suggests a savings of ~33% in prevention trial
cost when combining genetic and clinical variables as
risk predictors. In this case, both estimates are similar—
suggesting that the assumptions above do not qualitatively
affect the conclusions of our simulation-based analysis.
Type 2 Diabetes
To empirically evaluate the efficiency of T2D prevention
trials, we used data from the Whitehall II prospective
cohort study. This longitudinal study recruited a cohort
of civil servants, 25 to 55 years old in central London,
from 1985 to 1988 and followed them until 2003–2004.
The detailed design and data analysis were reported previ-
ously.27 Among 5,535 participants, we selected 1,916
prediabetic subjects with either impaired glucose tolerance
(IGT) (7.8–11.0 mmol/dl) or impaired fasting glucose (IFG)
level (5.6–6.9 mmol/dl) in the initial phase or clinical
examination to resemble subjects typically recruited in
a type 2 diabetes prevention trial.3
Using the Framingham offspring T2D risk scores calcu-
lated only from clinical variables,31 genetic risk scores
calculated from 20 robustly associated variants,18 and risk
scores calculated from both clinical and genetic factors,
we evaluated different strategies for trial enrichment.
Consistent with the previous study,27 we find that the
genetic risk scores alone do not effectively predict
onset of T2D in this cohort (AUC: 0.52). The Framingham
T2D risk scores from clinical variables (AUC: 0.75) or
combined risk scores (AUC: 0.76) were much more infor-
mative in predicting progression of diabetes among at-
risk individuals.
In this case, we estimate that clinical risk-score-based
enrichment trials using Framingham T2D risk scores can
reduce the trial cost by 35%, the sample size by 46%, or
the trial duration by 37% (compared to conventional trials
using only IFG/IGT status as eligibility criteria). We also
estimate that, in this case, using combined risk scores
that also include genetic information would result in negli-
gible additional benefits (Table 4). This finding reflects our
limited knowledge of the genetic variants contributing to
T2D risk (mirrored in their low AUC contribution) and is
much more pessimistic than the estimate of an ~11%
cost saving from our simulations.
Biobank-Driven Prevention Trial Designs
We also simulated biobank-driven enrichment trials,
which rely on a very large set of individuals for whom013
Figure 3. Sample Size and Total Cost of
Genetically Enriched Prevention Trials
Using Currently Known Risk Variants
x axis represents the targeted proportion of
individuals at high genetic risk, and the
left y axis, corresponding to solid lines,
represents sample size for a conventional
trial (red), on-trial sample size for a genetic
enrichment trial (blue), and screening
sample size for a genetic enrichment trial
(green). The right y axis, corresponding to
dashed lines, represents the total cost of
the genetic enrichment trial given targeted
proportion.genetic information is stored in a DNA biobank and
who have consented to being invited to participate in clin-
ical trials. Given planned biobanking efforts targeting
>100,000 individuals, this approach may allow identifica-
tion of individuals with very rare and very high-risk
genotypes for modest (incremental) screening cost. We
estimated the sample size, trial cost, and possible reduction
in trial durationwhen biobanks that were 1003 larger than
the planned on-trial sample sizes. In this case, individuals
in the top percentile of genetic risk might be targeted
(Table 3) and, except for very simple predictors like age,
traditional clinical risk factors would be ignored.
We estimate that such biobank-driven enrichment strat-
egies might reduce the trial cost by 41% for T2D, 58% for
AMD, 82% for T1D, and 41% for MI, when combined
with screening for clinical risk factors. These estimates
correspond to 20% to 37% in cost savings beyond those
available in standard genetic enrichment trials.
Prospect of Improved Genetic Risk Prediction
To assess the impact of future improvements in genetic risk
predictions, we simulated enrichment prevention trials by
using hypothetical sets of risk variants that might explain
25% or 50% of the heritability13 for the four disease traits
(Table S1). In these simulations, the genetic enrichment
prevention trials of T2D and MI are estimated to achieve
cost and trial size savings similar to those available forThe American Journal of HumaAMD and T1D. These results suggest
that more complete catalogs of dis-
ease risk alleles may substantially in-
crease the potential utility of genetic
information for trial enrichment.
Discussion
With rapid advances in high-
throughput biological screening strat-
egies, there is great hope that genetic
information will enable the design
of more efficient clinical trials and
that further gains in efficiency may
be provided by other genomic predic-
tors of disease (such as transcriptlevels, epigenomic modifications, and proteomic profiles).
Here, we evaluated the potential benefits of using genetic
information for designing prevention trials and derive
a framework for estimating the potential cost savings
when genetic information is used to identify at-risk indi-
viduals for inclusion in a trial.
Our results demonstrate that focusing on individuals
with high genetic risk may allow for reduced trial cost
and duration. Currently, benefits from genetic enrichment
trials are likely to be limited to diseases such as AMD
or T1D, where variants accounting for a large fraction of
the heritability have been identified. However, future
advances in genetic knowledge (driven by sequencing
studies and other studies of rare variation, for example)
should extend the utility of genetic enrichment trials to
broader sets of complex diseases, including conditions
for which genetic enrichment is currently unlikely to
succeed, such as T2D or MI.
It is important to note that the incremental value of
genetic information is dependent on the clinical variables
available and the populations and timescale of interest.
Recent studies on the AMD risk assessment from AREDs
subjects suggest that the improvement in AUC resulting
from genetic factors can be considerably lower when
additional clinical and demographic variables such as the
presence of large drusen, advanced AMD in one eye, and
family history are considered.32,33 When these additionaln Genetics 92, 547–557, April 4, 2013 553
Table 3. Sample Size, Cost, and Trial Duration of Enrichment Trials, Simulated from Published GWAS Risk Variants
Disease
Trait Trial Design
Optimized Trial Cost (Fixed Trial Duration) Reduced Trial Duration (Fixed No. Subjects)
%Targeted
Subjects
Trial No.
Subjects
Trial
Duration
Total
Cost ($)
%Targeted
Subjects
Trial No.
Subjects
Trial
Duration
Total
Cost ($)
T2D conventional trial 100% 231 3.0 years 4.5M 100% 231 3.0 years 4.5M
T2D genetic enrichment triala 43% 184 3.0 years 4.0M 20% 231 2.3 years 5.1M
T2D biobank enrichment trialb 1% 136 3.0 years 2.7M 1% 231 2.1 years 3.3M
AMD conventional trial 100% 1,342 5.0 years 25.5M 100% 1,342 5.0 years 25.5M
AMD genetic enrichment trial 31% 680 5.0 years 15.4M 20% 1,342 3.0 years 24.7M
AMD biobank enrichment trial 1% 565 5.0 years 10.7M 1% 1,342 3.0 years 16.1M
T1D conventional trial 100% 1,061 4.0 years 52.5M 100% 1,061 4.0 years 52.5M
T1D genetic enrichment trial 9% 260 4.0 years 17.1M 20% 1,061 1.5 years 27.4M
T1D biobank enrichment trial 1% 190 4.0 years 9.4M 1% 1,061 1.1 years 16.1M
MI conventional trial 100% 1,309 5.0 years 41.2M 100% 1,309 5.0 years 41.2M
MI genetic enrichment trial 34% 1,032 5.0 years 35.8M 20% 1,309 3.8 years 40.6M
MI biobank enrichment trial 1% 771 5.0 years 24.3M 1% 1,309 3.2 years 26.9M
aIn genetic enrichment trials, the cost-optimizing fraction of targeted samples subjects is selected for determining reduced trial cost, and 20% of targeted samples
subjects is selected for determining reduced trial duration.
bIn biobank-based enrichment, 1% of targeted samples subjects is assumed to determine trial cost and sample size reduction.covariates were included, overall AUC was considerably
increased, from 0.73 to 0.87, and addition of genetic
factors only marginally increased the AUC from 0.87 to
0.88. Most importantly, adjusting for the clinical variables,
the estimated hazard ratio for CFH and ARMS2 alleles
was substantially reduced from 1.97 to 1.28 and from
2.21 to 1.56, respectively. Therefore, in the AMD preven-
tion trials utilizing these additional clinical variables
described above, the benefit of genetic information might
be marginal. This suggests that—for AMD—much of the
genetic risk may be mediated by these strong clinical
predictors, and when these clinical predictors are included
in models of short-term risk, there is limited additional
predictive value in including genetic risk factors. In prac-
tice, it will be very useful to prospectively evaluate the
risk models including both genetic and environmental
risk factors in appropriate samples—a practice that is,
unfortunately, not yet common.
Our observation that very large gains in efficiency are
possible when DNA biobanks with genetic information
on hundreds of thousands of potential trial participants
is available is particularly interesting. In this setting, trials
can focus on individuals who carry very rare combinations
of many risk alleles. For example, by focusing on individ-
uals in the top 1% of the genetic risk of T1D, T2D, AMD,
or MI, we predict cost savings of 82%, 40%, 58%, and
41%. If basic clinical information is also stored in the bio-
bank, the potential efficiency gains will be even larger.
Our cost models assume a fixed cost of screening and
treatment. They do not allow for cost savings that may
be possible in very large screening efforts; or, conversely,
for cost increases that might result from the necessity of554 The American Journal of Human Genetics 92, 547–557, April 4, 2extending screening to additional sites. They also assume
that genetic risk factors do not impact treatment effi-
ciency—although that may not always be the case.
Interestingly, we note that the ratio of screening, genotyp-
ing, and on-trial costs has a noticeable impact on the
potential benefits of genetic information for trial design.
Because genetic information potentially allows for smaller
numbers of on-trial individuals, its benefits are particularly
important when the on-trial costs are large. For our
hypothetical AMD enrichment trials, an increase in on-
trial cost per subject from $3,500 to $20,000 would mean
that an enrichment strategy combining genetic and clin-
ical variables could enable a savings of ~42% in cost
(instead of a ~33% savings when the on-trial costs are
lower). As noted above, this savings will also be dependent
on the precise clinical variables available for study and the
incremental predictive power of genetic information over
these variables.
Our simulations required important assumptions—
particularly, the assumption that clinical and genetic risk
factors do not interact with each other. For T2D and
AMD, we were able to overcome this limitation by extend-
ing our analysis to also consider empirical samples that
included information on disease incidence as well as clin-
ical and genetic risk factors. Although similar empirical
assessments remain to be done for MI and T1D, we predict
that the outcome for MI will be similar to that for
T2D (where we conclude that currently available genetic
markers will typically have limited utility), and we expect
the situation for T1D might be more similar to that for
AMD (where currently available genetic markers can
already enable large cost savings). Future improvements013
Table 4. Sample Size, Cost, and Trial Duration of Enrichment Trials Based on Experimental Results23,27
Disease
Trait Trial Design
Optimized Trial Cost (Fixed Trial Duration) Reduced Trial Durationa (Fixed No. Subjects)
%Targeted
Subjects
Trial No.
Subjects
Trial
Duration
Total
Cost ($)
%Targeted
Subjects
Trial No.
Subjects
Trial
Duration
Total
Cost ($)
T2D conventional trialb 100% 231 3.0 years 4.51M 100% 231 3.0 years 4.51M
T2D clinical-only enrichment trialc 29% 124 3.0 years 2.92M 20% 231 1.9 years 3.95M
T2D combined (clinicalþgenetic)
enrichment triald
28% 120 3.0 years 2.84M 20% 231 1.9 years 3.93M
AMD conventional trialb 100% 1,342 5.0 years 25.5M 100% 1,342 5.0 years 25.5M
AMD clinical-only enrichment trialc 41% 1,018 5.0 years 21.8M 20% 1,342 3.8 years 28.5M
AMD combined (clinicalþgenetic)
enrichment triald
30% 753 5.0 years 17.2M 20% 1,342 3.2 years 25.7M
aCost-optimizing fraction of targeted samples subjects are selected for determining reduced trial cost, and 20% of targeted subjects are selected for determining
reduced trial duration.
bIn combined enrichment trial, we combine the clinical and genetic information and use this combined risk in the trial design.
cConventional trial uses only basic inclusion criteria—IFG or IGT status for T2D and baseline AMD grade R3.
dIn clinical-only enrichment trial, the clinical risk is calculated with a multitude of clinical factors including demographic and environmental factors.inmodeling will benefit from estimates of the performance
of combined genetic and clinical risk scores in prospective
studies.
By default, we assumed a multiplicative (or log-additive)
model for risk across loci. If an additive model were
assumed instead,34 the benefits from selecting individuals
with many risk alleles would be much smaller. Very large
prospective population screens are lacking, so this is an
assumption that needs validation. Limited reassurance is
available for some traits, such as macular degeneration,
where log-additive and additive models lead to different
risk predictions (AUC of >0.75 and ~0.57, respectively)
and published empirical data agrees well with the log-addi-
tive model predictions. For other traits, this is an issue that
deserves further empirical study. We note that genotype-
based enrollment (as with other trial enrichment strate-
gies) could limit the generalizability of trial results. In these
cases, demonstration of a benefit for genetically at-risk
individuals could be followed by a larger study evaluating
more general use of the treatment.
Here, we focused on evaluating the utility of genetic
information for enriching prevention trials. However, we
expect that the combination of genetic information and
clinical trials will be a fertile area of research—including
not just advances in trial design but also opportunities to
use genetic variants to understand the biology of drug
response and adverse events. In cases where screening for
clinical risk factors is laborious and expensive, genetic risk
scores may be used as a filter that focuses the clinical
screening on at-risk individuals (an example might be anti-
body test response screening used to identify individuals at
risk of developing T1D35). Finally, for common diseases
where thegenetic architecture ispoorlyunderstood, aproxy
for a high genetic risk score might be the presence of an
affected first-degree relative, such as a parent or sibling.
It should be noted that genetically enriched trials typi-
cally limit the application of treatment only to those withThe Amhigh genetic risk, because it is possible that the beneficial
effects are specific to the genetically enriched subjects (see
WebResources). However, once beneficial effects are shown
in an enriched trial, it could motivate a large study to eval-
uate the possibility for more general use of the treatment.
Ourmodel allows estimation of trial cost and duration in
a variety of enrichment scenarios, including eligibility
criteria based on clinical factors, genetic factors, or their
combination. Although we haven’t investigated multi-
arm trial designs, our work can model the utility of bio-
bank-driven enrichment (where genetic information may
be available for hundreds of thousands of individuals) or
of advances in genetic information. Code enabling others
to evaluate cost, sample size, and time requirements for
different trial designs is available from our website (see
Web Resources).Supplemental Data
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